Pregnancy

Organon Launches U.S. Grant Programs and Listening Tour as Part of “Her Plan Is Her Power,” Reaching High-Need Communities To Help Reduce Unplanned Pregnancies

U.S. grant programs include: Funding for select community health clinics in contraceptive deserts in Texas, Ohio and Georgia and product…

2 years ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing…

2 years ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C.…

2 years ago

Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™

- Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease -PRINCETON, N.J., Feb. 08,…

2 years ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight…

2 years ago

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…

2 years ago

Revolutionary AI-Driven Medtech Platform Changes the Way Patients Receive Quality Healthcare in the UK

LONDON, UK / ACCESSWIRE / February 6, 2024 / Access to efficient and convenient healthcare is vital in order to…

2 years ago

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

GE HealthCare receives FDA clearance for expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks.…

2 years ago

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

GE HealthCare receives FDA clearance for expanded indication for Novii+ maternal and fetal monitoring solution for pregnant patients ≥34 weeks.…

2 years ago